Fennec Pharmaceuticals Inc.

NasdaqCM:FENC Stok Raporu

Piyasa değeri: US$155.2m

Fennec Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Fennec Pharmaceuticals CEO'su Rosty Raykov, Jul2009 tarihinde atandı, in görev süresi 15.33 yıldır. in toplam yıllık tazminatı $ 2.54M olup, şirket hissesi ve opsiyonları dahil olmak üzere 23.9% maaş ve 76.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.24% ine doğrudan sahiptir ve bu hisseler $ 375.95K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.5 yıl ve 10.6 yıldır.

Anahtar bilgiler

Rosty Raykov

İcra Kurulu Başkanı

US$2.5m

Toplam tazminat

CEO maaş yüzdesi23.9%
CEO görev süresi15.3yrs
CEO sahipliği0.2%
Yönetim ortalama görev süresi4.5yrs
Yönetim Kurulu ortalama görev süresi10.6yrs

Son yönetim güncellemeleri

Recent updates

Improved Revenues Required Before Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Stock's 25% Jump Looks Justified

Nov 24
Improved Revenues Required Before Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Stock's 25% Jump Looks Justified

Revenues Working Against Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) Share Price

Oct 04
Revenues Working Against Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) Share Price

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Analysts Are More Bearish Than They Used To Be

Aug 15
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Analysts Are More Bearish Than They Used To Be

Is Fennec Pharmaceuticals (NASDAQ:FENC) A Risky Investment?

Jul 16
Is Fennec Pharmaceuticals (NASDAQ:FENC) A Risky Investment?

Lacklustre Performance Is Driving Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) 27% Price Drop

Jun 02
Lacklustre Performance Is Driving Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) 27% Price Drop

Risks To Shareholder Returns Are Elevated At These Prices For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

Apr 18
Risks To Shareholder Returns Are Elevated At These Prices For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

Earnings Update: Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Just Reported And Analysts Are Boosting Their Estimates

Nov 09
Earnings Update: Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Just Reported And Analysts Are Boosting Their Estimates

Fennec wins FDA approval of Pedmark for chemotherapy-induced ototoxicity in children

Sep 20

Buying Fennec Pharma Ahead Of September PDUFA For Pedmark

Aug 23

Fennec Pharmaceuticals secures up to $45M financing facility from Petrichor

Aug 01

Fennec Pharmaceuticals: Will Pedmark Make It To Market At Second Time Of Asking?

Oct 29

Fennec Could See Upside If Pedmark Gets Approved

Jul 29

Fennec Pharmaceuticals (FENC) Investor Presentation - Slideshow

Jun 18

Fennec Pharma resubmits PEDMARK application in U.S.

May 28

Fennec Pharmaceuticals (NASDAQ:FENC) Is In A Good Position To Deliver On Growth Plans

May 26
Fennec Pharmaceuticals (NASDAQ:FENC) Is In A Good Position To Deliver On Growth Plans

Breakeven On The Horizon For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

Apr 01
Breakeven On The Horizon For Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

Do Institutions Own Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Shares?

Mar 02
Do Institutions Own Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Shares?

CEO Tazminat Analizi

Rosty Raykov'un ücretlendirmesi Fennec Pharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$1m

Jun 30 2024n/an/a

US$3m

Mar 31 2024n/an/a

US$3m

Dec 31 2023US$3mUS$607k

-US$16m

Sep 30 2023n/an/a

-US$20m

Jun 30 2023n/an/a

-US$26m

Mar 31 2023n/an/a

-US$26m

Dec 31 2022US$614kUS$503k

-US$24m

Sep 30 2022n/an/a

-US$21m

Jun 30 2022n/an/a

-US$17m

Mar 31 2022n/an/a

-US$16m

Dec 31 2021US$3mUS$468k

-US$17m

Sep 30 2021n/an/a

-US$16m

Jun 30 2021n/an/a

-US$18m

Mar 31 2021n/an/a

-US$19m

Dec 31 2020US$2mUS$430k

-US$18m

Sep 30 2020n/an/a

-US$18m

Jun 30 2020n/an/a

-US$14m

Mar 31 2020n/an/a

-US$14m

Dec 31 2019US$1mUS$489k

-US$13m

Sep 30 2019n/an/a

-US$12m

Jun 30 2019n/an/a

-US$13m

Mar 31 2019n/an/a

-US$11m

Dec 31 2018US$1mUS$350k

-US$10m

Sep 30 2018n/an/a

-US$9m

Jun 30 2018n/an/a

-US$9m

Mar 31 2018n/an/a

-US$8m

Dec 31 2017US$450kUS$263k

-US$7m

Tazminat ve Piyasa: Rosty 'nin toplam tazminatı ($USD 2.54M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.46M ).

Tazminat ve Kazançlar: Rosty şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Rosty Raykov (48 yo)

15.3yrs

Görev süresi

US$2,540,940

Tazminat

Mr. Rostislav Raykov, also known as Rosty, has been the Chief Executive Officer of c Pharmaceuticals Inc. since July 2009. Mr. Raykov is an Independent Director of Lavras Gold Corp. since April 1, 2022. Mr...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Rostislav Raykov
CEO & Director15.3yrsUS$2.54m0.24%
$ 375.9k
Robert Andrade
Chief Financial Officer9yrsUS$1.31m0.46%
$ 720.9k
Terry Evans
Chief Commercial Officerless than a yearVeri yokVeri yok
Pierre Sayad
Chief Medical Officerless than a yearVeri yokVeri yok
Christiana Cioffi
Chief Strategy Officerless than a yearVeri yokVeri yok
Mark Gowland
Controller9yrsVeri yokVeri yok
Lei Fang
President of Pharstat Incno dataVeri yokVeri yok

4.5yrs

Ortalama Görev Süresi

Deneyimli Yönetim: FENC 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.5 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Rostislav Raykov
CEO & Director15.3yrsUS$2.54m0.24%
$ 375.9k
Chris Rallis
Independent Director13.3yrsUS$173.18k0.18%
$ 275.2k
Khalid Islam
Independent Chairman of the Board10.6yrsUS$225.23k0.78%
$ 1.2m
Jodi Cook
Independent Director5.2yrsUS$153.81k0%
$ 0
Marco Brughera
Independent Director8.3yrsUS$166.31k0%
$ 0

10.6yrs

Ortalama Görev Süresi

69yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: FENC 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 10.6 yıldır).